Screener
Neurocrine Biosciences NBIX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total other income (expense), net | 53.4 | (8.9) |
| Income before provision for income taxes | 246.8 | 14.7 |
| Provision for income taxes | 48.9 | 6.8 |
| Net income | $197.9 | $7.9 |
| Foreign currency translation adjustments, net of tax | — | 1.5 |
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | (12.7) | 1.7 |
| Comprehensive income | $185.2 | $11.1 |
| Earnings per share: |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's net income?
- Neurocrine Biosciences (NBIX) reported net income of $197.9M in Q1 2026.
- How has Neurocrine Biosciences's net income changed year-over-year?
- Neurocrine Biosciences's net income increased by 2405.1% year-over-year, from $7.9M to $197.9M.
- What is the long-term trend for Neurocrine Biosciences's net income?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's net income has grown at a 49.1% compound annual growth rate (CAGR), from $96.9M to $478.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Neurocrine Biosciences's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude